Qiagen Receives Notification of BlackRock’s Voting Rights

An announcement from Qiagen ( (QGEN) ) is now available.

Qiagen N.V. has been notified by the Netherlands Authority for the Financial Markets (AFM) about a voting rights announcement involving BlackRock, Inc. The notification, which was disclosed on the AFM website, details BlackRock’s indirect holdings in Qiagen. This announcement highlights BlackRock’s significant capital interest and voting rights in Qiagen, which could influence the company’s governance and decision-making processes. The disclosure underscores the importance of institutional investors in shaping the strategic direction of companies within the biotechnology sector.

The most recent analyst rating on (QGEN) stock is a Hold with a $42.50 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.

More about Qiagen

Qiagen N.V. operates in the biotechnology industry, focusing on providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is known for its products and services that enable the extraction, purification, and analysis of DNA, RNA, and proteins.

Average Trading Volume: 1,339,003

Technical Sentiment Signal: Sell

Current Market Cap: $8.89B

For an in-depth examination of QGEN stock, go to TipRanks’ Stock Analysis page.